Mesenchymal stromal cells for the treatment of Alzheimer’s disease: Strategies and limitations
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a major cause of age-related dementia and is characterized by progressive brain damage that gradually destroys memory and the ability to learn, which ultimately leads to the decline of a patient’s ability to perform daily activities. Although some of the pharmacological treatments of AD are available for symptomatic relief, they are not able to limit the progression of AD and have several side effects. Mesenchymal stem/stromal cells (MSCs) could be a potential therapeutic option for treating AD due to their immunomodulatory, anti-inflammatory, regenerative, antioxidant, anti-apoptotic, and neuroprotective effects. MSCs not only secret neuroprotective and anti-inflammatory factors to promote the survival of neurons, but they also transfer functional mitochondria and miRNAs to boost their bioenergetic profile as well as improve microglial clearance of accumulated protein aggregates. This review focuses on different clinical and preclinical studies using MSC as a therapy for treating AD, their outcomes, limitations and the strategies to potentiate their clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 13×
“In fact, both Aβ aggregation and tau hyperphosphorylation can directly increase oxidative stress, since Aβ can act as an oxidant while hyperphosphorylated tau induces neuroinflammation and the consequent microglial ROS production (Nunomura et al., 2006; Alavi Naini and Soussi-Yanicostas, 2015; Cheignon et al., 2018).”
BackgroundInfluentialNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 1×
“In fact, both Aβ aggregation and tau hyperphosphorylation can directly increase oxidative stress, since Aβ can act as an oxidant while hyperphosphorylated tau induces neuroinflammation and the consequent microglial ROS production (Nunomura et al., 2006; Alavi Naini and Soussi-Yanicostas, 2015; Cheignon et al., 2018).”
BackgroundMicroglia and macrophages in brain homeostasis and disease
Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999 · cited 2×
“They are involved in immune surveillance, pathogen defense, and maintenance of homeostasis in the brain (Li and Barres, 2018).”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 1×
“Mutations in APP, PS1, and PS2 alter normal APP processing and produce the neurotoxic Aβ oligomer that gives rise to Aβ-induced neurotoxicity and aggregation of Aβ plagues (Benilova et al., 2012).”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“Under normal brain physiology, microglia are responsible for the clearance and degradation of extracellular Aβ, which they recognize through microglial integrin receptors and recruitment of several enzymes such as the pro-inflammatory matrix metalloproteinases (MMPs) to restrict the formation of Aβ plaques (Konnecke a…”
BackgroundNeuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 1×
“However, while transient neuroinflammation is beneficial for neurogenesis and aggregate clearance, excessive or chronic neuroinflammation that fails to resolve itself can worsen AD symptoms due to ROS generation, necrosis, and collateral tissue damage in the brain (DiSabato et al., 2016; Schain and Kreisl, 2017; Yong…”
BackgroundNeutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 1×
“Downregulated glucose transport to the brain during AD progression also accelerates BBB breakdown and Aβ pathology, since the loss of glucose contributes to an energy deficiency that induces neuron necrosis and the resulting neuroinflammation (Nelson et al., 2016; Montagne et al., 2017).”
Background
Cited by
The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
Česnik, A. B., & Švajger, U. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1400347 · Cited by 128
Therapeutic Effects of Mesenchymal Stromal Cells Require Mitochondrial Transfer and Quality Control
Mukkala, A. N., Jerkic, M., Khan, Z., Szaszi, K., Kapus, A., & Rotstein, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115788 · Cited by 45
“These disorders are the foremost cause of disability and the second leading cause of death worldwide [208–210].”
BackgroundVargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
Metadata
- Authors
- Regmi, S., Liu, D. D., Shen, M., Kevadiya, B. D., Ganguly, A., Primavera, R., Chetty, S., Yarani, R., & Thakor, A. S.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-10-06
- Volume
- 15
- Pages
- 1011225-1011225
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W4302291043
- Cited by
- 51
- References
- 30
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stromal cells for the treatment of Alzheimer’s disease: Strategies and limitations. https://app.cochat.ai/papers/10.3389/fnmol.2022.1011225
- The paper
- Regmi, S., Liu, D. D., Shen, M., Kevadiya, B. D., Ganguly, A., Primavera, R., Chetty, S., Yarani, R., & Thakor, A. S. (2022). Mesenchymal stromal cells for the treatment of Alzheimer’s disease: Strategies and limitations. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2022.1011225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.